We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK-based life sciences group Abzena has signed a licensing contract and a master service and clinical supply agreement with Taiwan, Chinaese biopharmaceutical company OBI Pharma to enable process development and manufacturing using ThioBridge.